Back to News
Market Impact: 0.38
Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & OutlookProduct Launches
Compass Pathways said it remains on track to complete a rolling New Drug Application submission for COMP360 in Q4 2026. The planned filing follows positive Phase III studies of its synthetic psilocybin treatment for treatment-resistant depression, a key regulatory milestone that could materially advance the company's lead asset.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.58
Ticker Sentiment
CMPS0.78
More News
- Trump Says US Team Met With Iranians at UNGA
- Paramount will need to release way more movies to make this merger work
- Meta is breaking out after introducing Muse AI agent. Where the stock is going, according to the charts
- Heidi CEO on AI in Healthcare, $900M valuation
- Meta’s Muse AI is exploding in popularity—and already drawing heated backlash from another tech giant
- Royal Caribbean nears $3 billion deal to take 50% equity stake in Sandals